Jacobs Levy Equity Management, Inc Entrada Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 210,873 shares of TRDA stock, worth $1.5 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
210,873
Previous 212,717
0.87%
Holding current value
$1.5 Million
Previous $3.68 Million
48.16%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding TRDA
# of Institutions
111Shares Held
28.7MCall Options Held
8.2KPut Options Held
2.3K-
Baker Bros. Advisors LP New York, NY4.87MShares$34.6 Million0.52% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$31.4 Million27.61% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$31.2 Million57.03% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.74MShares$19.5 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X02.12MShares$15.1 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $223M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...